Ménière’s Disease Is Associated with Single Nucleotide Polymorphisms in the Human Potassium Channel Genes, KCNE1 and KCNE3Doi K. · Sato T. · Kuramasu T. · Hibino H. · Kitahara T. · Horii A. · Matsushiro N. · Fuse Y. · Kubo T.
Department of Otolaryngology and Sensory Organ Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Although the bases for both the sporadic and inherited forms of Ménière’s disease (MD) remain undefined, it is likely to be multifactorial, one of the factors being a genetic predisposition. Recently, genetic association studies on complex diseases have become very popular and most of them are case-control studies using single nucleotide polymorphisms (SNPs) as markers. Mutations/polymorphisms in KCNE potassium channel genes might play a causative role in MD, because KCNE potassium channels have been suggested to be present and active in transmembrane ion and water transports in the inner ear. In the present study, to identify MD susceptibility genes, we have conducted a genetic association study with optimized sampling, optimized phenotyping/genotyping, and a selection of KCNE genes as the candidate genes. The SNPs analyses identified 112G/A SNP in the KCNE1 gene and 198T/C SNP in the KCNE3 gene in 63 definite MD cases as well as 205 and 237 non-MD control subjects. For both KCNE1 and KCNE3 genes, a significant difference in frequency of each SNP was confirmed between MD cases and non-MD control subjects. The result indicates that 112G/A SNP in the KCNE1 gene and 198T/C SNP in the KCNE3 gene could determine an increased susceptibility to develop MD.
© 2005 S. Karger AG, Basel
- Morrison AW: Anticipation in Meniere’s disease. J Laryngol Otol 1995;109:499–502.
- Hegele RA: SNP judgments and freedom of association. Arterioscler Thromb Vasc Biol 2002;22:1058–1061.
- Abbott GW, Goldstein SAN: Physiology and pathophysiology of the MinK-related peptides (MiRPs). Mol Interv 2001;1:95–107.
- Schroeder BC, Waldegger S, Fehr S, Bleich M, Warth R, Greger R, Jentsch TJ: A constitutively open potassium channel formed by KCNE1 and KCNE3. Nature 2000;403:196–199.
- Vetter DE, Mann JR, Wangemann P, Liu J, McLaughlin KJ, Lesage F, Marcus DC, Lazdunski M, Heinemann SF, Barhanin J: Inner ear defects induced by null mutation of the IsK gene. Neuron 1996;17:1251–1264.
- Schulze-Bahr E, Wang Q, Wedekind H, Haverkamp W, Chen Q, Sun Y: KCNE1 mutations cause Jervell and Lange-Nielsen syndrome. Nat Genet 1997;17:267–268.
- Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, Keating MT, Goldstein SAN: MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999;97:175–187.
Doi K, Sato T, Kuramasu T, Matsushiro N, Fuse Y, Kubo T: Single nucleotide polymorphism (SNP) analyses of genes encoding KCNE potassium channels in Meniere’s disease; in Meniere’s Disease and Inner Ear Homeostasis Disorders, in press.
- Committee on Hearing and Equilibrium: Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Menière’s disease. Otolaryngol Head Neck Surg 1995;113:181–185.
- Lemaire FX, Feenstra L, Huygen PL, Fransen E, Devriendt K, Van Camp G, Vantrappen G, Cremers CWRJ: Progressive late-onset sensorineural hearing loss and vestibular impairment with vertigo (DFNA9/COCH): longitudinal analyses in a Belgian family. Otol Neurotol 2003;24:743–748.
- Lopez-Escamez JA, Lopez-Nevot A, Cortes R, Ramal L, Lopez-Nevot MA: Expression of A, B, C, and DR antigens in definite Meniere’s disease in a Spanish population. Eur Arch Otorhinolaryngol 2002;259:347–350.
- Lynch M, Cameron TL, Knight M, Kwok TY, Thomas P, Forrest SM, Giersch ABS, Briggs RJS, Pyman BC: Structural mutational analysis of antiquitin as a candidate gene for Meniere’s disease. Am J Med Genet 2002;110:397–399.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.